Justin C Lee, MD
Cardiovascular Disease (Cardiology) · Emeryville
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 10
- 2 carriers
- Offices
- 5
Offices
5 locations · Stanford Health Care · University Healthcare Alliance
Looking this up.
Hospitals listed: Alta Bates Summit Medical Center · Alta Bates Summit Medical Center - Alta Bates Camp · Eden Medical Center · Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
10 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Lee’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
10 of 10 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence C146229 · Current
Licensed to practise in California · since 2016 · expires 2028-10-31 · University of Illinois College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Washington MD.MD.00042338Physician And Surgeon License · since 2003 · expires 2027-10-05ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alta Bates Summit Medical CenterOakland, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 130.09 (87.72 to 172.46) · 109 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.227, Oct 2024 – Sep 2025
- Alta Bates Summit Medical Center - Alta Bates CampBerkeley, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.298, Oct 2024 – Sep 2025
- Eden Medical CenterCastro Valley, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 75% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.122, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Alta Bates Summit Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 4 better, 3 the same, 0 worse of 7 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 130.09 (87.72 to 172.46) · 109 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.227 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0.06 to 1.94) · 1,209 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.6 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.8 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.7 · 341 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 381 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 2,811 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.31) · 7,167 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,659 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.93 (0.92 to 4.94) · 1,668 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.25 (0 to 2.75) · 580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.67 (1.19 to 4.15) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.17 (0.33 to 12.02) · 633 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.11 (4.67 to 11.55) · 619 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.07) · 309 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.39 (0 to 0.96) · 6,085 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 217 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.724 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.425 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.716 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.7 · 416 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 606 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.4 · 359 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.8 · 555 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -14.4 · 358 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16 · 382 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.2 to 8.2) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.3 to 16) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.5 · 232 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.9 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.8 (11.1 to 20) · 251 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 579 cases | No different | Jan 2024 – Dec 2024 |
What patients said (535 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Alta Bates Summit Medical Center - Alta Bates Camp
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 6 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.298 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.18 (0.16 to 2.2) · 730 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.51 to 1.23) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 188.12 (132.31 to 243.94) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 50 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 189 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.6 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,585 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,929 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 3,954 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.95 to 5.36) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0 to 3.33) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.99 (0.39 to 3.59) · 717 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.85 (2.27 to 19.44) · 326 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.79 (1.08 to 8.49) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.19 to 3.18) · 184 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.17 (0 to 0.88) · 3,240 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 161 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.207 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.48 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.785 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.4 · 243 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -58.2 · 194 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -12.3 · 177 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 209 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.8 to 7.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.2 (9.4 to 15.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.8 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 81 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (10 to 18.1) · 315 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.2) · 137 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 15% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Eden Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.122 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.89) · 819 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.46 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 137.41 (92.94 to 181.88) · 70 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.4 · 78 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 38 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.1 · 207 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 359 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 355 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 1,714 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.39) · 4,697 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.1 to 0.5) · 4,676 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.69 (0.53 to 4.85) · 860 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.56 (0 to 3.24) · 251 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.75 (1.17 to 4.32) · 818 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.76 (0 to 15.78) · 261 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.09 (2.08 to 10.1) · 242 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.64 (0.16 to 3.12) · 233 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.85) · 4,132 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 60 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.431 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.292 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.307 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.61 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 258 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 22.6 · 225 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 2.4 · 367 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 390 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 58 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 88 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.9 (9.6 to 17.4) · 68 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 205 cases | No different | Jan 2024 – Dec 2024 |
What patients said (431 patients answered, 17% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 58% |
| "YES", patients would definitely recommend the hospital | 75% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$646,877
Medicare paid this office $646,877 for 3,186 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 1,320 | $187,912 | $140 |
| Return visit (30+ min) | 1,265 | $136,084 | $97 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 261 | $101,310 | $388 |
| Long return visit (40+ min) | 197 | $30,581 | $138 |
| New patient visit (45+ min) | 223 | $28,254 | $127 |
See all 35 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 1,320 | $187,912 | $140 |
| Return visit (30+ min) | 1,265 | $136,084 | $97 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 261 | $101,310 | $388 |
| Long return visit (40+ min) | 197 | $30,581 | $138 |
| New patient visit (45+ min) | 223 | $28,254 | $127 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 221 | $22,560 | $51 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 1,690 | $20,686 | $11 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 83 | $17,696 | $213 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 230 | $14,142 | $61 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 900 | $13,866 | $14 |
| Programming of dual lead pacemaker system | 140 | $11,500 | $65 |
| Ultrasound of both sides of head and neck blood flow | 53 | $10,041 | $189 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 440 | $9,308 | $21 |
| New patient visit (60+ min) | 34 | $6,224 | $183 |
| Injection, regadenoson, 0.1 mg | 201 | $3,868 | None |
| Heart rhythm recording of continous external ekg over 8-15 days | 271 | $3,164 | $11 |
| Ultrasound scan of abdominal aorta | 27 | $2,420 | $86 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 314 | $2,019 | $6 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 109 | $1,910 | $18 |
| Heart muscle strain imaging | 47 | $1,810 | $39 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 75 | $1,735 | $22 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 75 | $1,714 | $23 |
| Programming of dual lead implantable defibrillator system | 20 | $1,515 | $66 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 22 | $1,278 | $58 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 76 | $1,116 | $14 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 40 | $1,088 | $27 |
| Programming of single lead pacemaker system | 16 | $1,087 | $54 |
| Electrocardiogram (ecg) 2-day continuous | 67 | $1,043 | $15 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 55 | $1,042 | $19 |
| Ultrasound of heart, follow-up | 22 | $1,037 | $41 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 56 | $678 | $12 |
| Injection, aminophyllin, up to 250 mg | 82 | $554 | None |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 53 | $524 | $10 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 25 | $427 | $17 |
| Ultrasound of heart blood flow, valves and chambers | 11 | $320 | $29 |
Who their Medicare patients are
3,186 Original Medicare patients in 2024. Average age 78 · Under 65 3% · 85 and older 23% · Women 55% · Also on Medicaid 59% · Health risk score 1.38. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Diabetes 37% · Coronary heart disease 32% · Chronic kidney disease 31% · Atrial fibrillation 28% · Heart failure 22% · Depression 16% · Cancer 13% · COPD 13% · Stroke 10% · Dementia 8%.
The office billed $4,258,043, Medicare allowed $954,203 and paid $646,877; for 10,132 services of 56 kinds; $5,181 of it was for drugs given in the office and $641,697 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 3,186 | 10,132 | 78 | 1.38 | $4,258,043 | $646,877 |
| 2023 | 2,290 | 6,086 | 78 | 1.66 | $2,231,461 | $390,147 |
| 2022 | 2,365 | 6,890 | 78 | 1.52 | $2,426,794 | $446,606 |
| 2021 | 2,448 | 6,976 | 78 | 1.59 | $2,422,801 | $475,070 |
| 2020 | 1,870 | 3,840 | 78 | 1.82 | $1,454,069 | $291,877 |
| 2019 | 2,192 | 5,013 | 78 | 1.81 | $2,331,953 | $416,356 |
| 2018 | 2,078 | 5,068 | 78 | 1.71 | $2,233,303 | $405,866 |
| 2017 | 800 | 1,643 | 77 | 1.65 | $783,779 | $154,491 |
| 2016 | 43 | 55 | 69 | 1.43 | $7,012 | $1,553 |
| 2013 | 95 | 148 | 69 | 1.77 | $27,887 | $5,242 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 30 services
| Return visit (30+ min) | 1,067 | $99,341 | $89 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 545 | $81,964 | $150 |
| Long return visit (40+ min) | 143 | $24,107 | $145 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 102 | $20,346 | $105 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 59 | $19,131 | $314 |
| New patient visit (45+ min) | 141 | $17,445 | $124 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 83 | $14,128 | $21 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 1,121 | $12,736 | $11 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 194 | $11,862 | $61 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 60 | $10,480 | $175 |
| Programming of dual lead pacemaker system | 117 | $9,945 | $60 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 57 | $9,201 | $153 |
| New patient visit (60+ min) | 51 | $9,062 | $178 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 93 | $6,834 | $23 |
| Injection, regadenoson, 0.1 mg | 38 | $6,121 | None |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 95 | $6,039 | $21 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 38 | $3,766 | $50 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 42 | $3,297 | $70 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 52 | $2,924 | $56 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 22 | $2,530 | $115 |
| Influenza vaccine split virus, preservative free | 28 | $2,014 | $72 |
| Programming of single lead pacemaker system | 22 | $1,846 | $58 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 56 | $1,454 | $26 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 62 | $1,417 | $23 |
| Heart muscle strain imaging | 30 | $1,145 | $38 |
| Administration of influenza virus vaccine | 28 | $1,016 | $36 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 24 | $552 | $23 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 41 | $508 | $12 |
| Heart rhythm recording of continous external ekg over 8-15 days | 35 | $393 | $11 |
| Injection, aminophyllin, up to 250 mg | 13 | $90 | None |
2022: 31 services
| Return visit (30+ min) | 1,062 | $101,244 | $90 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 626 | $87,843 | $139 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 98 | $37,774 | $382 |
| Long return visit (40+ min) | 190 | $30,558 | $143 |
| New patient visit (45+ min) | 163 | $19,593 | $120 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 80 | $16,269 | $22 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 92 | $15,611 | $90 |
| Programming of dual lead pacemaker system | 144 | $14,875 | $71 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 1,266 | $14,832 | $11 |
| Injection, regadenoson, 0.1 mg | 74 | $14,352 | None |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 175 | $10,912 | $62 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 56 | $9,753 | $171 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 46 | $9,112 | $198 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 80 | $8,473 | $53 |
| New patient visit (60+ min) | 47 | $8,204 | $175 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 87 | $7,141 | $24 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 89 | $6,589 | $22 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 92 | $5,524 | $60 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 52 | $4,525 | $61 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 25 | $2,975 | $119 |
| Heart muscle strain imaging | 71 | $2,727 | $38 |
| Influenza vaccine split virus, preservative free | 31 | $2,125 | $69 |
| Programming of single lead pacemaker system | 23 | $1,708 | $53 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 63 | $1,229 | $20 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 47 | $1,212 | $26 |
| Administration of influenza virus vaccine | 31 | $1,118 | $36 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 14 | $810 | $58 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 43 | $542 | $13 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 29 | $538 | $19 |
| Ultrasound of heart blood flow, valves and chambers | 16 | $275 | $17 |
| Injection, aminophyllin, up to 250 mg | 31 | $189 | None |
2021: 36 services
| Return visit (30+ min) | 992 | $105,818 | $103 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 619 | $104,685 | $168 |
| Long return visit (40+ min) | 172 | $30,510 | $156 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 83 | $22,978 | $277 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 94 | $18,605 | $95 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 95 | $18,278 | $23 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 82 | $17,964 | $219 |
| New patient visit (45+ min) | 134 | $17,281 | $129 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 1,282 | $15,725 | $11 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 237 | $15,677 | $64 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 74 | $14,418 | $183 |
| Programming of dual lead pacemaker system | 152 | $13,428 | $66 |
| New patient visit (60+ min) | 48 | $9,387 | $196 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 111 | $8,317 | $26 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 41 | $8,103 | $99 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 93 | $7,252 | $25 |
| Injection, regadenoson, 0.1 mg | 37 | $7,032 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 69 | $6,176 | $66 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 31 | $3,845 | $124 |
| Heart muscle strain imaging | 90 | $3,842 | $42 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 68 | $3,818 | $56 |
| Telephone medical discussion with physician, 11-20 minutes | 76 | $2,161 | $28 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 80 | $1,713 | $21 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 84 | $1,705 | $20 |
| Influenza vaccine split virus, preservative free | 23 | $1,501 | $65 |
| Programming of single lead pacemaker system | 20 | $1,425 | $57 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 11 | $1,264 | $22 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 19 | $1,174 | $33 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 51 | $992 | $19 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 70 | $919 | $13 |
| Ultrasound scan of abdominal aorta | 11 | $684 | $57 |
| Administration of influenza virus vaccine | 23 | $488 | $21 |
| Ultrasound of heart, follow-up | 17 | $394 | $23 |
| Injection, aminophyllin, up to 250 mg | 40 | $279 | None |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 15 | $99 | $7 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 17 | $49 | $3 |
2020: 33 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 425 | $69,250 | $162 |
| Return visit (30+ min) | 457 | $36,001 | $71 |
| Telephone medical discussion with physician, 11-20 minutes | 388 | $25,492 | $63 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 271 | $18,430 | $68 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 90 | $15,666 | $96 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 31 | $15,421 | $497 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 76 | $14,796 | $185 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 56 | $12,095 | $216 |
| New patient visit (45+ min) | 86 | $10,677 | $124 |
| Telephone medical discussion with physician, 21-30 minutes | 101 | $9,208 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 73 | $7,260 | $66 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 32 | $6,304 | $99 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 59 | $6,167 | $24 |
| New patient visit (60+ min) | 32 | $5,788 | $181 |
| Injection, regadenoson, 0.1 mg | 29 | $5,468 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 364 | $4,833 | $12 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 32 | $4,038 | $126 |
| Long return visit (40+ min) | 22 | $3,305 | $132 |
| Programming of dual lead pacemaker system | 48 | $3,034 | $51 |
| Telephone medical discussion with physician, 5-10 minutes | 90 | $2,869 | $32 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 36 | $2,181 | $61 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 35 | $2,126 | $26 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 30 | $1,958 | $27 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 56 | $1,055 | $19 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 50 | $1,050 | $21 |
| Influenza vaccine split virus, preservative free | 11 | $671 | $61 |
| Heart muscle strain imaging | 16 | $668 | $42 |
| Ultrasound of heart, follow-up | 15 | $359 | $24 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 21 | $277 | $13 |
| Administration of influenza virus vaccine | 11 | $226 | $21 |
| Injection, aminophyllin, up to 250 mg | 26 | $178 | None |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 13 | $88 | $7 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 13 | $39 | $3 |
2019: 28 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 623 | $101,647 | $161 |
| Return visit (30+ min) | 936 | $90,494 | $82 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 72 | $34,351 | $471 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 155 | $31,861 | $94 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 124 | $26,432 | $211 |
| New patient visit (45+ min) | 172 | $23,087 | $134 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 284 | $18,973 | $66 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 84 | $15,898 | $181 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 71 | $13,610 | $96 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 819 | $12,334 | $14 |
| Injection, regadenoson, 0.1 mg | 63 | $11,524 | None |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 83 | $4,832 | $58 |
| Programming of dual lead pacemaker system | 49 | $3,923 | $52 |
| Long return visit (40+ min) | 24 | $3,221 | $124 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 45 | $3,213 | $64 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 122 | $2,669 | $22 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 124 | $2,608 | $21 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 15 | $1,736 | $24 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,476 | $123 |
| Short return visit (20+ min) | 16 | $932 | $58 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 14 | $871 | $62 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 11 | $653 | $26 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 28 | $547 | $20 |
| Injection, aminophyllin, up to 250 mg | 60 | $372 | None |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 28 | $367 | $13 |
| Ultrasound of heart, follow-up | 14 | $329 | $24 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 12 | $80 | $7 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 18 | $53 | $3 |
2018: 22 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 541 | $97,833 | $179 |
| Return visit (30+ min) | 882 | $89,256 | $80 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 189 | $34,647 | $93 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 132 | $28,523 | $214 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 52 | $25,647 | $493 |
| New patient visit (45+ min) | 167 | $22,783 | $136 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 117 | $21,490 | $176 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 309 | $20,569 | $65 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 991 | $15,695 | $13 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 52 | $9,929 | $95 |
| Injection, regadenoson, 0.1 mg | 49 | $8,551 | None |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 54 | $3,201 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 45 | $3,105 | $63 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 140 | $2,923 | $21 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 131 | $2,825 | $22 |
| Short return visit (20+ min) | 59 | $2,578 | $44 |
| Programming of dual lead pacemaker system | 40 | $2,469 | $45 |
| Long return visit (40+ min) | 13 | $1,653 | $127 |
| Ultrasound of heart, follow-up | 13 | $323 | $23 |
| Injection, aminophyllin, up to 250 mg | 36 | $171 | None |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 13 | $92 | $7 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 23 | $69 | $3 |
2017: 17 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 227 | $47,817 | $211 |
| Return visit (30+ min) | 267 | $26,734 | $97 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 28 | $13,637 | $487 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 50 | $12,651 | $253 |
| New patient visit (45+ min) | 73 | $10,351 | $142 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 40 | $5,752 | $91 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 29 | $5,391 | $93 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 92 | $5,247 | $56 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 315 | $5,191 | $15 |
| Injection, regadenoson, 0.1 mg | 27 | $4,691 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 37 | $2,898 | $63 |
| Short return visit (20+ min) | 36 | $2,416 | $67 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 18 | $2,146 | $119 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 30 | $1,905 | $64 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 49 | $1,207 | $25 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 51 | $1,172 | $23 |
| Injection, aminophyllin, up to 250 mg | 27 | $177 | None |
2016: 1 service
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 25 | $175 | $6 |
2013: 3 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 17 | $1,501 | $68 |
| Return visit (30+ min) | 13 | $1,091 | $73 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 57 | $300 | $5 |
Medicaid work
$146,823 in 2024
Medicaid paid $146,823 for 5,618 billed services this clinician did in 2024, up to 177 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 1,033 | $40,092 |
| Return visit (30+ min) | 1,077 | $35,982 |
| Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection | 148 | $28,407 |
| Injection, regadenoson, 0.1 mg | 182 | $13,750 |
| Long return visit (40+ min) | 120 | $5,519 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 1,503 | $4,249 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with supervision by a physician or other qualified health care professional | 103 | $3,479 |
| External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; recording (includes connection and initial recording) | 301 | $2,860 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 96 | $2,767 |
| New patient visit (45+ min) | 49 | $2,701 |
| Tc99m sestamibi | 132 | $1,900 |
| External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation | 351 | $1,760 |
| 2024 | 5,618 | 22 | 177 | $146,823 |
| 2023 | 4,278 | 17 | 178 | $62,454 |
| 2022 | 3,649 | 12 | 160 | $35,572 |
| 2021 | 4,221 | 18 | 158 | $50,592 |
| 2020 | 1,575 | 11 | 104 | $28,860 |
| 2019 | 2,709 | 8 | 107 | $57,530 |
| 2018 | 2,435 | 7 | 94 | $52,365 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 880 | $29,499 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 709 | $20,391 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 1,268 | $3,478 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system, leadless pacemaker system, or implantable defibrillator system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | 258 | $2,411 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, including analysis of 1 or more recorded physiologic cardiovascular data elements from all internal and external sensors, analysis, review(s) and report(s) by a physician or other qualified health care professional | 557 | $1,738 |
| Long return visit (40+ min) | 29 | $1,278 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with supervision by a physician or other qualified health care professional | 68 | $1,111 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system, or leadless pacemaker system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional | 240 | $927 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 16 | $638 |
| Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional; dual lead pacemaker system | 18 | $431 |
| Myocardial strain imaging using speckle tracking-derived assessment of myocardial mechanics (List separately in addition to codes for echocardiography imaging) | 13 | $127 |
| External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; recording (includes connection and initial recording) | 18 | $116 |
2022
| Return visit (30+ min) | 899 | $17,411 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 560 | $12,002 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 1,217 | $3,145 |
| Long return visit (40+ min) | 44 | $748 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, including analysis of 1 or more recorded physiologic cardiovascular data elements from all internal and external sensors, analysis, review(s) and report(s) by a physician or other qualified health care professional | 383 | $600 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 55 | $539 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system, leadless pacemaker system, or implantable defibrillator system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | 170 | $508 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with supervision by a physician or other qualified health care professional | 24 | $363 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system, or leadless pacemaker system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional | 137 | $178 |
| DOPPLER ECHO PULSE WAVE W/SPECTRAL F-UP/LMTD STD | 27 | $40 |
| Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography) | 27 | $38 |
| Advance Care Planning discussed and documented advance care plan or surrogate decision maker documented in the medical record (DEM) (GER, Pall Cr) | 106 | $0 |
2021
| Return visit (30+ min) | 982 | $27,678 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 652 | $11,626 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with supervision by a physician or other qualified health care professional | 81 | $2,584 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 1,203 | $2,265 |
| Injection, regadenoson, 0.1 mg | 13 | $1,609 |
| Long return visit (40+ min) | 26 | $791 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 18 | $604 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system, leadless pacemaker system, or implantable defibrillator system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | 251 | $596 |
| Short return visit (20+ min) | 32 | $583 |
| CARDIOVASCULAR STRESS TEST | 34 | $549 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, including analysis of 1 or more recorded physiologic cardiovascular data elements from all internal and external sensors, analysis, review(s) and report(s) by a physician or other qualified health care professional | 508 | $501 |
| Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography) | 85 | $352 |
2020
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 496 | $15,771 |
| Return visit (30+ min) | 360 | $8,686 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with supervision by a physician or other qualified health care professional | 36 | $2,045 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 283 | $735 |
| Short return visit (20+ min) | 27 | $628 |
| Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | 62 | $324 |
| DOPPLER ECHO PULSE WAVE W/SPECTRAL F-UP/LMTD STD | 37 | $226 |
| Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography) | 41 | $208 |
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 11-20 minutes of medical discussion | 122 | $140 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, including analysis of 1 or more recorded physiologic cardiovascular data elements from all internal and external sensors, analysis, review(s) and report(s) by a physician or other qualified health care professional | 40 | $97 |
| Advance Care Planning discussed and documented advance care plan or surrogate decision maker documented in the medical record (DEM) (GER, Pall Cr) | 71 | $0 |
2019
| Return visit (30+ min) | 791 | $26,047 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 671 | $19,997 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with supervision by a physician or other qualified health care professional | 153 | $7,460 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 726 | $1,724 |
| DOPPLER ECHO PULSE WAVE W/SPECTRAL F-UP/LMTD STD | 158 | $944 |
| Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography) | 166 | $931 |
| CARDIOVASCULAR STRESS TEST | 29 | $428 |
| Advance Care Planning discussed and documented advance care plan or surrogate decision maker documented in the medical record (DEM) (GER, Pall Cr) | 15 | $0 |
2018
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 552 | $16,963 |
| Return visit (30+ min) | 457 | $16,314 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with supervision by a physician or other qualified health care professional | 196 | $11,373 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 814 | $2,993 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 14 | $1,918 |
| DOPPLER ECHO PULSE WAVE W/SPECTRAL F-UP/LMTD STD | 196 | $1,405 |
| Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography) | 206 | $1,400 |
Drugs they prescribed that Part D paid
$1,804,903
Pharmacies billed $1,804,903 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 6,668) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
5,310 generic and 1,358 brand-name prescriptions · $1,804,903 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 698 | $1,055,451 | $1,512 |
| Xarelto | 159 | $210,949 | $1,327 |
| Entresto | 102 | $149,893 | $1,470 |
| Jardiance | 139 | $132,747 | $955 |
| Farxiga | 73 | $75,123 | $1,029 |
See all 50 drugs
| Eliquis | 698 | $1,055,451 | $1,512 |
| Xarelto | 159 | $210,949 | $1,327 |
| Entresto | 102 | $149,893 | $1,470 |
| Jardiance | 139 | $132,747 | $955 |
| Farxiga | 73 | $75,123 | $1,029 |
| Repatha Sureclick | 38 | $26,731 | $703 |
| Brilinta | 22 | $23,192 | $1,054 |
| Candesartan Cilexetil | 230 | $19,477 | $85 |
| Multaq | 11 | $18,421 | $1,675 |
| Metoprolol | 919 | $14,875 | $16 |
| Atorvastatin | 1,102 | $8,760 | $8 |
| Amiodarone | 71 | $5,939 | $84 |
| Flecainide Acetate | 65 | $3,302 | $51 |
| Nitroglycerin | 335 | $3,089 | $9 |
| Ezetimibe | 102 | $2,649 | $26 |
| Carvedilol | 373 | $2,625 | $7 |
| Isosorbide Dinitrate | 21 | $2,323 | $111 |
| Isosorbide Mononitrate Er | 123 | $2,150 | $17 |
| Rosuvastatin | 95 | $2,061 | $22 |
| Valsartan | 76 | $1,893 | $25 |
| Digoxin | 64 | $1,384 | $22 |
| Diltiazem 24hr Er (Cd) | 43 | $1,247 | $29 |
| Spironolactone | 178 | $1,235 | $7 |
| Losartan | 140 | $1,058 | $8 |
| Amlodipine Besylate | 284 | $1,004 | $4 |
| Olmesartan Medoxomil | 74 | $985 | $13 |
| Bisoprolol | 24 | $959 | $40 |
| Clopidogrel | 108 | $903 | $8 |
| Verapamil Er | 40 | $874 | $22 |
| Diltiazem 24hr Er (Xr) | 16 | $848 | $53 |
| Ranolazine Er | 12 | $839 | $70 |
| Labetalol | 18 | $824 | $46 |
| Diltiazem 24hr Er | 13 | $754 | $58 |
| Hydralazine | 58 | $742 | $13 |
| Furosemide | 138 | $708 | $5 |
| Prasugrel | 22 | $686 | $31 |
| Nifedipine Er | 23 | $579 | $25 |
| Potassium Chloride | 29 | $560 | $19 |
| Lisinopril | 89 | $543 | $6 |
| Metoprolol | 101 | $490 | $5 |
| Irbesartan | 18 | $385 | $21 |
| Diltiazem | 22 | $384 | $17 |
| Atenolol | 31 | $308 | $10 |
| Famotidine | 21 | $285 | $14 |
| Hydrochlorothiazide | 46 | $151 | $3 |
| Warfarin | 14 | $139 | $10 |
| Propranolol | 13 | $136 | $10 |
| Meclizine | 17 | $129 | $8 |
| Benazepril | 16 | $94 | $6 |
| Simvastatin | 19 | $63 | $3 |
Year by year
| 2024 | 6,668 | 1,362 | 0% (0) | 20% | $1,804,903 |
| 2023 | 4,976 | 1,099 | 0% (0) | 18% | $1,526,332 |
| 2022 | 3,810 | 946 | 0% (0) | 17% | $881,290 |
| 2021 | 3,537 | 864 | 0% (0) | 16% | $607,963 |
| 2020 | 2,899 | 622 | 0% (0) | 15% | $370,319 |
| 2019 | 2,755 | 626 | 0% (0) | 12% | $288,377 |
| 2018 | 1,891 | 499 | 0% (0) | 17% | $195,457 |
| 2017 | 260 | 143 | 0% (0) | 25% | $19,844 |
| 2016 | 68 | 31 | 0% (0) | 31% | $3,095 |
| 2014 | 86 | 40 | None | 24% | $2,238 |
| 2013 | 559 | 151 | None | None | $13,787 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 46 drugs
| Eliquis | 509 | $847,481 | $1,665 |
| Xarelto | 107 | $185,257 | $1,731 |
| Entresto | 97 | $163,516 | $1,686 |
| Jardiance | 31 | $50,664 | $1,634 |
| Farxiga | 30 | $46,757 | $1,559 |
| Atorvastatin | 822 | $23,914 | $29 |
| Metoprolol | 680 | $22,787 | $34 |
| Brilinta | 15 | $21,719 | $1,448 |
| Repatha Sureclick | 13 | $17,720 | $1,363 |
| Praluent | 26 | $15,956 | $614 |
| Carvedilol | 362 | $9,144 | $25 |
| Amlodipine Besylate | 248 | $5,697 | $23 |
| Isosorbide Mononitrate Er | 106 | $5,567 | $53 |
| Candesartan Cilexetil | 49 | $4,999 | $102 |
| Valsartan | 71 | $4,864 | $69 |
| Nitroglycerin | 265 | $4,403 | $17 |
| Flecainide Acetate | 58 | $3,987 | $69 |
| Amiodarone | 59 | $3,947 | $67 |
| Ezetimibe | 50 | $3,121 | $62 |
| Losartan | 89 | $3,112 | $35 |
| Rosuvastatin | 59 | $2,977 | $50 |
| Diltiazem 24hr Er (Cd) | 47 | $2,880 | $61 |
| Isosorbide Dinitrate | 22 | $2,664 | $121 |
| Digoxin | 54 | $2,585 | $48 |
| Hydralazine | 60 | $2,534 | $42 |
| Spironolactone | 102 | $2,245 | $22 |
| Olmesartan Medoxomil | 41 | $2,237 | $55 |
| Metoprolol | 97 | $2,122 | $22 |
| Clopidogrel | 76 | $2,087 | $27 |
| Lisinopril | 82 | $1,795 | $22 |
| Bumetanide | 14 | $1,322 | $94 |
| Potassium Chloride | 33 | $1,269 | $38 |
| Midodrine | 13 | $1,256 | $97 |
| Furosemide | 118 | $1,231 | $10 |
| Bisoprolol | 13 | $1,138 | $88 |
| Labetalol | 15 | $1,040 | $69 |
| Verapamil Er | 22 | $1,020 | $46 |
| Diltiazem | 29 | $968 | $33 |
| Diltiazem 24hr Er (Xr) | 16 | $911 | $57 |
| Nifedipine Er | 16 | $887 | $55 |
| Irbesartan | 11 | $672 | $61 |
| Ventolin Hfa | 11 | $646 | $59 |
| Montelukast | 16 | $560 | $35 |
| Simvastatin | 18 | $430 | $24 |
| Hydrochlorothiazide | 41 | $303 | $7 |
| Atenolol | 21 | $303 | $14 |
2022: 41 drugs
| Eliquis | 328 | $468,061 | $1,427 |
| Xarelto | 107 | $143,826 | $1,344 |
| Entresto | 66 | $87,533 | $1,326 |
| Pradaxa | 21 | $27,371 | $1,303 |
| Praluent | 17 | $14,687 | $864 |
| Metoprolol | 569 | $13,613 | $24 |
| Atorvastatin | 643 | $10,099 | $16 |
| Flecainide Acetate | 49 | $5,272 | $108 |
| Valsartan | 66 | $4,836 | $73 |
| Carvedilol | 277 | $4,755 | $17 |
| Ezetimibe | 53 | $4,503 | $85 |
| Nitroglycerin | 194 | $3,126 | $16 |
| Digoxin | 47 | $3,083 | $66 |
| Isosorbide Dinitrate | 17 | $2,671 | $157 |
| Isosorbide Mononitrate Er | 101 | $2,588 | $26 |
| Rosuvastatin | 43 | $2,371 | $55 |
| Diltiazem 24hr Er (Cd) | 40 | $1,855 | $46 |
| Amlodipine Besylate | 182 | $1,678 | $9 |
| Losartan | 92 | $1,445 | $16 |
| Nifedipine Er | 20 | $1,350 | $67 |
| Midodrine | 11 | $1,328 | $121 |
| Potassium Chloride | 34 | $1,313 | $39 |
| Hydralazine | 48 | $1,279 | $27 |
| Clopidogrel | 45 | $1,077 | $24 |
| Labetalol | 12 | $1,035 | $86 |
| Lisinopril | 73 | $873 | $12 |
| Diltiazem 24hr Er | 22 | $846 | $38 |
| Spironolactone | 45 | $791 | $18 |
| Amiodarone | 14 | $696 | $50 |
| Olmesartan Medoxomil | 31 | $683 | $22 |
| Dilt-Xr | 14 | $674 | $48 |
| Metoprolol | 73 | $673 | $9 |
| Ventolin Hfa | 11 | $670 | $61 |
| Furosemide | 88 | $632 | $7 |
| Verapamil Er | 11 | $448 | $41 |
| Pravastatin | 15 | $385 | $26 |
| Atenolol | 19 | $281 | $15 |
| Hydrochlorothiazide | 48 | $239 | $5 |
| Diltiazem | 20 | $238 | $12 |
| Meclizine | 12 | $171 | $14 |
| Simvastatin | 16 | $120 | $8 |
2021: 42 drugs
| Eliquis | 229 | $297,009 | $1,297 |
| Xarelto | 132 | $141,102 | $1,069 |
| Pradaxa | 26 | $26,327 | $1,013 |
| Entresto | 30 | $24,860 | $829 |
| Metoprolol | 532 | $15,286 | $29 |
| Brilinta | 11 | $13,272 | $1,207 |
| Praluent | 15 | $9,150 | $610 |
| Atorvastatin | 590 | $7,879 | $13 |
| Nitroglycerin | 227 | $4,297 | $19 |
| Carvedilol | 248 | $4,190 | $17 |
| Valsartan | 51 | $3,205 | $63 |
| Diltiazem 24hr Er (Cd) | 37 | $3,026 | $82 |
| Rosuvastatin | 33 | $2,709 | $82 |
| Isosorbide Dinitrate | 19 | $2,323 | $122 |
| Ezetimibe | 38 | $2,293 | $60 |
| Isosorbide Mononitrate Er | 98 | $2,056 | $21 |
| Nifedipine Er | 21 | $2,003 | $95 |
| Losartan | 103 | $1,605 | $16 |
| Digoxin | 32 | $1,576 | $49 |
| Amlodipine Besylate | 189 | $1,496 | $8 |
| Verapamil Sr | 11 | $1,227 | $112 |
| Hydralazine | 50 | $1,083 | $22 |
| Potassium Chloride | 27 | $992 | $37 |
| Labetalol | 15 | $840 | $56 |
| Spironolactone | 49 | $819 | $17 |
| Diltiazem 24hr Er | 14 | $797 | $57 |
| Furosemide | 92 | $791 | $9 |
| Clopidogrel | 50 | $771 | $15 |
| Cartia Xt | 12 | $727 | $61 |
| Olmesartan Medoxomil | 13 | $710 | $55 |
| Irbesartan | 19 | $643 | $34 |
| Metoprolol | 86 | $607 | $7 |
| Lisinopril | 65 | $506 | $8 |
| Amiodarone | 22 | $434 | $20 |
| Verapamil Er | 13 | $347 | $27 |
| Hydrochlorothiazide | 51 | $332 | $7 |
| Pravastatin | 13 | $302 | $23 |
| Atenolol | 25 | $250 | $10 |
| Simvastatin | 14 | $176 | $13 |
| Lovastatin | 11 | $164 | $15 |
| Clonidine | 16 | $138 | $9 |
| Meclizine | 11 | $126 | $11 |
2020: 39 drugs
| Eliquis | 178 | $190,311 | $1,069 |
| Xarelto | 63 | $67,047 | $1,064 |
| Pradaxa | 21 | $18,353 | $874 |
| Entresto | 13 | $13,710 | $1,055 |
| Metoprolol | 403 | $10,801 | $27 |
| Atorvastatin | 459 | $5,979 | $13 |
| Carvedilol | 250 | $2,967 | $12 |
| Potassium Chloride | 26 | $2,642 | $102 |
| Isosorbide Dinitrate | 18 | $2,502 | $139 |
| Nitroglycerin | 145 | $2,453 | $17 |
| Nifedipine Er | 19 | $2,210 | $116 |
| Digoxin | 34 | $2,059 | $61 |
| Isosorbide Mononitrate Er | 113 | $2,019 | $18 |
| Ezetimibe | 29 | $1,868 | $64 |
| Losartan | 86 | $1,362 | $16 |
| Hydralazine | 51 | $1,205 | $24 |
| Amiodarone | 29 | $1,121 | $39 |
| Diltiazem 24hr Er (Cd) | 27 | $1,118 | $41 |
| Irbesartan | 17 | $1,100 | $65 |
| Valsartan | 14 | $927 | $66 |
| Cartia Xt | 14 | $874 | $62 |
| Dilt-Xr | 13 | $830 | $64 |
| Amlodipine Besylate | 154 | $772 | $5 |
| Rosuvastatin | 27 | $684 | $25 |
| Olmesartan Medoxomil | 11 | $662 | $60 |
| Clopidogrel | 50 | $661 | $13 |
| Warfarin | 41 | $616 | $15 |
| Furosemide | 63 | $576 | $9 |
| Metoprolol | 88 | $562 | $6 |
| Lisinopril | 64 | $520 | $8 |
| Enalapril Maleate | 12 | $492 | $41 |
| Spironolactone | 30 | $406 | $14 |
| Verapamil Er | 20 | $344 | $17 |
| Famotidine | 12 | $280 | $23 |
| Atenolol | 18 | $253 | $14 |
| Hydrochlorothiazide | 49 | $250 | $5 |
| Lovastatin | 13 | $186 | $14 |
| Benazepril | 14 | $157 | $11 |
| Simvastatin | 18 | $130 | $7 |
2019: 34 drugs
| Eliquis | 159 | $131,931 | $830 |
| Xarelto | 54 | $45,239 | $838 |
| Entresto | 19 | $15,837 | $834 |
| Metoprolol | 361 | $12,697 | $35 |
| Pradaxa | 16 | $9,669 | $604 |
| Atorvastatin | 450 | $7,509 | $17 |
| Carvedilol | 277 | $4,095 | $15 |
| Isosorbide Dinitrate | 23 | $3,300 | $143 |
| Rosuvastatin | 30 | $2,882 | $96 |
| Isosorbide Mononitrate Er | 117 | $2,724 | $23 |
| Potassium Chloride | 25 | $2,130 | $85 |
| Nitroglycerin | 113 | $1,993 | $18 |
| Nifedipine Er | 23 | $1,921 | $84 |
| Losartan | 72 | $1,264 | $18 |
| Ezetimibe | 13 | $1,203 | $93 |
| Amlodipine Besylate | 187 | $1,173 | $6 |
| Hydralazine | 60 | $1,165 | $19 |
| Diltiazem 24hr Er (Cd) | 27 | $1,154 | $43 |
| Valsartan | 11 | $808 | $73 |
| Digoxin | 13 | $790 | $61 |
| Amiodarone | 25 | $775 | $31 |
| Cartia Xt | 25 | $752 | $30 |
| Lisinopril | 89 | $723 | $8 |
| Clopidogrel | 42 | $586 | $14 |
| Warfarin | 41 | $566 | $14 |
| Spironolactone | 29 | $565 | $19 |
| Metoprolol | 76 | $516 | $7 |
| Furosemide | 56 | $450 | $8 |
| Diltiazem | 11 | $297 | $27 |
| Hydrochlorothiazide | 38 | $237 | $6 |
| Simvastatin | 24 | $207 | $9 |
| Losartan-Hydrochlorothiazide | 11 | $168 | $15 |
| Lovastatin | 14 | $166 | $12 |
| Atenolol | 13 | $148 | $11 |
2018: 30 drugs
| Eliquis | 160 | $91,161 | $570 |
| Xarelto | 62 | $39,929 | $644 |
| Entresto | 15 | $10,300 | $687 |
| Metoprolol | 214 | $7,450 | $35 |
| Pradaxa | 15 | $6,092 | $406 |
| Atorvastatin | 248 | $4,274 | $17 |
| Isosorbide Dinitrate | 15 | $2,197 | $146 |
| Carvedilol | 209 | $2,096 | $10 |
| Potassium Chloride | 20 | $1,832 | $92 |
| Nitroglycerin | 74 | $1,735 | $23 |
| Isosorbide Mononitrate Er | 72 | $1,678 | $23 |
| Amiodarone | 14 | $1,128 | $81 |
| Warfarin | 51 | $1,013 | $20 |
| Cartia Xt | 27 | $986 | $37 |
| Digoxin | 13 | $904 | $70 |
| Rosuvastatin | 20 | $857 | $43 |
| Amlodipine Besylate | 113 | $714 | $6 |
| Losartan | 64 | $632 | $10 |
| Metoprolol | 92 | $518 | $6 |
| Diltiazem 24hr Er (Cd) | 11 | $444 | $40 |
| Lisinopril | 57 | $444 | $8 |
| Hydralazine | 23 | $385 | $17 |
| Furosemide | 39 | $348 | $9 |
| Spironolactone | 12 | $332 | $28 |
| Clopidogrel | 15 | $279 | $19 |
| Hydrochlorothiazide | 26 | $157 | $6 |
| Lovastatin | 13 | $149 | $11 |
| Simvastatin | 17 | $83 | $5 |
| Atenolol | 22 | $79 | $4 |
| Clonidine | 13 | $72 | $6 |
2017: 12 drugs
| Eliquis | 14 | $7,765 | $555 |
| Metoprolol | 31 | $1,724 | $56 |
| Atorvastatin | 31 | $670 | $22 |
| Nitroglycerin | 13 | $500 | $38 |
| Warfarin | 11 | $254 | $23 |
| Isosorbide Mononitrate Er | 11 | $153 | $14 |
| Carvedilol | 17 | $150 | $9 |
| Amlodipine Besylate | 15 | $115 | $8 |
| Metoprolol | 20 | $106 | $5 |
| Losartan | 12 | $104 | $9 |
| Furosemide | 11 | $58 | $5 |
| Lisinopril | 11 | $44 | $4 |
2014: 2 drugs
| Metoprolol | 14 | $807 | $58 |
| Carvedilol | 18 | $138 | $8 |
2013: 14 drugs
| Metoprolol | 42 | $2,964 | $71 |
| Dilt-Xr | 30 | $2,359 | $79 |
| Carvedilol | 73 | $800 | $11 |
| Atorvastatin | 38 | $795 | $21 |
| Isosorbide Mononitrate Er | 33 | $714 | $22 |
| Nitroglycerin Patch | 15 | $680 | $45 |
| Losartan | 31 | $318 | $10 |
| Lisinopril | 39 | $298 | $8 |
| Simvastatin | 36 | $262 | $7 |
| Metoprolol | 36 | $247 | $7 |
| Warfarin | 24 | $230 | $10 |
| Pravastatin | 11 | $207 | $19 |
| Furosemide | 33 | $197 | $6 |
| Lovastatin | 11 | $134 | $12 |
Money from drug and device companies
$33 in 2025
| 2025 | 1 | 1 | None | $33 |
| 2024 | 1 | 1 | None | $24 |
| 2023 | 1 | 1 | None | $100 |
| 2022 | 1 | 2 | None | $168 |
| 2021 | 2 | 5 | None | $254 |
| 2019 | 2 | 2 | None | $111 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Novartis Pharmaceuticals | Leqvio | $33 | 1 payment
|
See the published payment
| Novartis Pharmaceuticals | Meals · 2025-10-17 | Leqvio | $33 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $24
| Abiomed | Impella | $24 | 1 payment
|
2023: $100
| GlaxoSmithKline | Arexvy | $100 | 1 payment
|
2022: $168
| Biotronik | Orsiro Mission | $168 | 2 payments
|
2021: $254
| Boston Scientific | Watchman | $168 | 3 payments
|
| Biotronik | Solia | $87 | 2 payments
|
2019: $111
| Regeneron Pharmaceuticals | Praluent | $92 | 1 payment
|
| Regeneron Healthcare Solutions | Praluent | $19 | 1 payment
|
Professional record
- NPI
- 1225078579
- Licence
- CA C146229, WA MD00042338California C146229: Current · expires 2028-10-31Washington MD.MD.00042338: Active
- Trained
- University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb), 1999
- Group
- Stanford Health Care · University Healthcare Alliance
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- WA 8417545
- Taxonomy
- Cardiology (207RC0000X); Internal medicine (207R00000X); Pediatrics (208000000X)
- Mailing address
- 388 9th St Ste 250, Oakland, CA, 94607
- NPI first listed
- 2006-06-07
- NPI last updated
- 2024-04-22
- NPI record certified
- 2024-04-22
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 365 Hawthorne Ave Ste 201, Oakland, CA, 94609